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Abstract
Introduction Early multimodal treatment of severe sepsis,
including the use of drotrecogin alfa (activated) (DrotAA) when
indicated, is considered essential for optimum outcome.
However, predicting which infected patients will progress to
severe sepsis and the need for aggressive intervention
continues to be problematic. We therefore wished to explore
whether there were any potential early markers that might
predict improved survival in response to early use of DrotAA in
patients with severe sepsis. In particular, in the dynamic setting
of severe sepsis, we postulated that changes in markers
reflecting evolving rather than baseline clinical status might
guide therapy.
Methods Data on a cohort of 305 Canadian patients from the
open label ENHANCE trial of DrotAA in severe sepsis was
retrospectively analyzed to search for potential clinical
predictors of outcome in severe sepsis. Patients received a 96-
hour infusion of DrotAA and were followed for 28 days. The
association between time to treatment and mortality within
subgroups defined by dynamic changes in various potential
markers was explored.
Results Mortality at 28 days was 22.6% and the variables of
age, time to treatment, and early changes in serum creatinine
and platelet count were identified by logistic regression as
independent predictors of mortality. Across all age ranges, 28-
day mortality was lower when DrotAA was administered within
24 hours of first sepsis-induced organ dysfunction compared to
administration after 24 hours for both subgroups of patients
defined by changes in platelet count and creatinine within the
first day.
Conclusions These findings suggest that when indicated,
treatment with DrotAA should be initiated as soon as possible,
regardless of age.
Trial Registration Previous trial registration number:
NCT00568893
Introduction
Severe sepsis is a complex infection-induced syndrome asso-
ciated with high morbidity and mortality. Although the case
fatality rate of severe sepsis may be decreasing, it remains
unacceptably high at 20 to 35% and because the incidence of
severe sepsis is steadily increasing, the total number of deaths
continues to increase [1-3].
In the setting of severe sepsis, early multi-modal, goal-directed
therapy including early antimicrobial administration are recom-
mended components of emergency treatment [4-9]; however,
there is often underutilization and delay in the use of therapies
with proven efficacy [4,5,10,11]. Although early changes in
organ failure and even changes in clinical status within the first
day are prognostic [12,13], clinicians commonly struggle to
APACHE: Acute Physiologic and Chronic Health Evaluation; APC: activated protein C; DrotAA: Drotrecogin alfa activated; ENHANCE: Extended 
Evaluation of Recombinant Human Activated Protein C; SD: standard deviation; SIRS: systemic inflammatory response syndrome; SOFA: Sequential 
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identify risk factors that might reliably predict progression of
infection to severe sepsis, septic shock, and death, which
could signal the need for early aggressive intervention [14,15].
Mortality from severe sepsis correlates with the number of
organ dysfunctions[12]. One of the hallmarks of severe sepsis
that leads to organ dysfunction is a profound disturbance of
the microvascular circulation [16,17]. The response to infec-
tion is associated with a simultaneous activation of inflamma-
tion and the coagulation cascade, and suppression of
fibrinolysis. This results in significant microvascular dysfunc-
tion and amplification of the pro-inflammatory and pro-coagu-
lant processes in many tissues, which thereby augments organ
dysfunction [6,16,18].
Drotrecogin alfa (activated) (DrotAA) is a form of recombinant
human activated protein C (APC), which has been shown to
significantly reduce mortality from severe sepsis and septic
shock in patients with two or more organ failures [6,19].
DrotAA is recommended as part of a 'sepsis bundle' together
with an early goal-directed approach to resuscitation
[4,5,11,20].
Although the precise mechanism of clinical benefit of APC is
uncertain, it may in part be derived from a modulating effect on
microvascular inflammation and coagulation [21]. APC is
present in concentrations ranging from 3 to 5 μg/mL in healthy
adults and reduction of these concentrations below 50% of
normal predisposes to thrombosis, predominantly in the
venous system. When protein C becomes activated (APC) it
has anti-thrombotic, pro-fibrinolytic and anti-inflammatory
properties [16,20-22] that are important in combating microv-
ascular coagulation and inflammation in sepsis. The mecha-
nism of its benefit in these patients appears to be in part
through direct interactions with the endothelium [21]. APC
can inhibit endothelial cell apoptosis and also has a direct
effect on endothelial cytoskeletal rearrangement that strength-
ens endothelial tight junctions [21]. Another direct mechanism
of action of APC on the endothelium is modulation of the
endothelial monolayer, leading to increased cell-cell contact
and decreased permeability [23].
The ENHANCE (Extended Evaluation of Recombinant Human
Activated Protein C) study was an open-label study (n = 2378)
of DrotAA in severe sepsis, undertaken to accumulate further
evidence for the efficacy and safety of DrotAA treatment in
severe sepsis [6]. The study found that treatment within 24
hours from first organ failure was significantly associated with
lower mortality and the authors concluded that "more effective
use of drotrecogin alfa (activated) might be obtained by initiat-
ing therapy earlier".
Because there is also continuing uncertainty regarding the
predictors of outcome in severe sepsis, the present study had
two objectives: first, to attempt to identify early predictors of
mortality evident within the first day; and second to further
understand how these predictors may be associated with sur-
vival in subgroups of patients (i.e. prognostic value). These
represent data that would be crucial to clinicians managing
these complex cases.
Clinicians often categorize acutely ill patients as being 'stable',
'worsening', or 'improving', although there is no consensus on
what is objectively meant by these terms. Nevertheless, classi-
fying patients in this way might conceivably alter the approach
to management, specifically the level of aggressiveness of
treatment. For example, in the setting of severe sepsis, there is
an emerging clinical consensus that merely stable portends a
worse outcome than improving [12]. We therefore also
wished to explore whether there was a relation between the
patient's apparent clinical status defined in terms of dynamic
variables (i.e. stable, worsening, or improving), the use of
DrotAA and outcome.
To this end, the Canadian ENHANCE investigators used the
Canadian cohort's database to conduct an exploratory retro-
spective analysis. This cohort represents a robust, homogene-
ous population with relatively uniform processes of care when
compared with the international cohort, and is a suitable pop-
ulation with which to explore these hypotheses.
Materials and methods
Eli Lilly granted permission to use data from the original
ENHANCE trial for the current analysis. Institutional review
board consent for this retrospective data review was not
sought as the Informed Consent Document for the original
ENHANCE trial included provisions for retrospective review.
The first patient was enrolled in the international study in
March 2001 and the final patients completed the follow-up
period in January 2003.
Canadian sites had received institutional review board
approval and appropriate informed consent was obtained from
all patients. Data from all patients enrolled in the 21 Canadian
sites of the multinational open-label ENHANCE trial [6] (25
countries, 361 sites, 2378 patients) were selected for this
report. All patients (n = 305) received study drug infusion and
were assessed at 28 days post-infusion.
All patients had known or suspected infection and manifested
systemic inflammatory response syndrome (SIRS) defined by
the presence of at least three of four SIRS criteria [24]. In addi-
tion, patients had one or more acute sepsis-induced organ
dysfunctions (cardiovascular, respiratory, renal, hematologic,
or metabolic acidosis) of 48 hours or less. Patients considered
to be at high risk for clinically important bleeding, or with
known hypocoagulable or hypercoagulable conditions were
excluded. A full description of the inclusion and exclusion cri-
teria have been previously published [19].Available online http://ccforum.com/content/13/3/R78
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DrotAA (Xigris©, Eli Lilly and Co., Indianapolis, IN, USA) was
infused in an unblinded fashion in all patients at a dose of 24
μg/kg/hour for 96 hours within 48 hours of the diagnosis of the
first organ dysfunction. Standard supportive care was pro-
vided until discharge.
The primary endpoint was all-cause mortality at 28 days. From
the 48-hour period prior to infusion until day 28 post-infusion,
organ function, markers of disease severity, incidence and
type of infection, and other laboratory tests were assessed.
Throughout the 28-day period, vital signs, infection status,
transfusion status, and adverse events were recorded.
This was a retrospective exploratory analysis rather than a pro-
spective trial, and one of our objectives was to explore whether
there was a relation between the patient's dynamic clinical sta-
tus (i.e. stable, worsening, or improving), the use of DrotAA,
and outcome. However, because different physicians may
view stable as either 'good' (i.e. same category as improving)
or 'bad' (i.e. same category as worsening), we chose to con-
sider a single composite clinical status category, namely 'sta-
ble/worsening'. Furthermore, because these potentially
prognostic terms are only loosely defined, we attempted to
objectify the definitions for the present analysis in terms of
changes in commonly measurable clinical parameters. Follow-
ing the results of multivariate logistic regression while adjust-
ing for multiple co-variates, variables identified to be
statistically significant in the bivariate analysis were fitted into
a logistic regression model. Based on this analysis, we chose
to define the term stable/worsening in terms of dynamic
changes from baseline in serum creatinine and platelet counts.
Additional details on this methodology are described in the
results section below.
Statistical analysis
Descriptive statistics, including mean, standard deviation,
count, and percentages, were performed on baseline charac-
teristics and disease severity markers for the Canadian sam-
ple. Baseline demographics, disease severity, and clinical
variables that were associated with mortality were compared
in a bivariate analysis between survivors and non-survivors.
One-sided Wilcoxon rank sums test were used for continuous
variables and Chi-square or Fisher's exact tests were used for
categorical variables.
We wished also to explore whether there was a relation
between the patient's apparent clinical status (ie. stable, wors-
ening, or improving), the use of DrotAA, and outcome. How-
ever, because there is no consensus on these clinical
definitions of stability and because different physicians view
stable as either good (i.e. same category as improving) or bad
(same category as worsening), we chose to consider a single
composite clinical status category, namely stable or worsen-
ing, as there is an emerging clinical consensus that stable por-
tends a worse outcome than improving [12].
Separate analyses were performed for time to treatment and
mortality rate on the stable/worsening clinical status sub-
group. Twenty-eight-day mortality was compared between
patients who received early treatment (defined as less than 24
hours from first sepsis-induced organ dysfunction to start of
infusion of DrotAA) and those who received late treatment (24
hours or more to start of infusion of DrotAA). The analysis was
repeated for each category of clinical status using Cochran-
Mantel-Haenszel statistics. The Breslow-Day test was used to
examine time to treatment and age interactions.
To identify possible predictors of mortality, multivariate logistic
regression was used while adjusting for multiple co-variates.
Variables identified to be statistically significant in the bivariate
analysis were fitted into a logistic regression model. Correla-
tions between the variables that were retained in the model
using the stepwise method with a significance level of 0.05
were examined for multicollinearity.
Odds ratio estimates, 95% confidence intervals, and P values
were generated. A few variables were rescaled so that the
odds ratio estimates reflected incremental changes at respec-
tive intervals. Although the variables remained as continuous
variables, the variables for change from baseline to day 1 in
creatinine concentration and platelet count were divided by 50
for convenience in reporting.
We also sought to explore whether the timing by clinically
important intervals would stand as an independent predictor of
survival. Following extensive exploratory analysis, we identified
that a six hour cutoff increment appeared to make a difference
in terms of survival, and so the variable for time from first sep-
sis-induced organ dysfunction to start of study drug was
divided by six in order to determine if there were differences in
outcome by six-hour intervals from onset of organ dysfunction
to treatment. Age was classified into four groups (≤49, 50 to
64, 65 to 74, and ≥75 years of age) to aid in clinical interpre-
tation.
All statistical tests were performed at an alpha level of 0.05.
There was no adjustment for multiple comparisons.
Results
Baseline characteristics and outcome
The Canadian cohort from the international ENHANCE study
contained 305 patients enrolled at 21 sites across Canada
(see list of investigators), 141 (46%) of whom received
DrotAA within the first 24 hours and 164 (54%) of whom
received DrotAA after 24 hours. Patient demographics and
disease severity are summarized in Table 1. Half of the
patients (50.2%) had organ dysfunction in each of the cardio-
vascular, renal, and respiratory systems, indicating that this
was a severely ill cohort.Critical Care    Vol 13 No 3    Hodder et al.
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28-day mortality analysis
Exploratory analysis of the differences between survivors (n =
236) and non-survivors (n = 69) for the Canadian cohort
revealed the significant or clinically important variables listed in
Table 2. These variables were then used in a bivariate analysis
of survivors and non-survivors and the results are presented in
Table 3. Age, an increase in serum creatinine from baseline to
day 1, a decrease in platelet count from baseline to day 1, the
number of organ dysfunctions at baseline, and pre-infusion
Acute Physiology and Chronic Health Evaluation (APACHE) II
score were significantly associated with 28-day mortality.
Thus, non-survivors at 28 days were on average older, had
more severe disease at baseline and had greater early pro-
gression of renal and hematological dysfunction.
Although time to treatment was not statistically significant in
this bivariate analysis, the variable was retained in subsequent
analyses based on results from the full ENHANCE trial, which
demonstrated that time to treatment within 24 hours from first
organ failure was significantly associated with lower mortality.
In addition, we felt that timing was an important clinical issue,
and that there might be other factors confounding the associ-
ation between mortality and treatment.
Table 1
Patient baseline characteristics and disease severity markers for patients receiving DrotAA
Variable Canadian sites (n = 305)
Gender, % male 57.7
Mean age, years (SD) 56.9 (17.2)
Mean APACHE II (SD) 25.3 (7.8)
Mean number of organ dysfunctions (SD) 3.1 (1.2)
Mean SOFA score (SD) 10.9 (3.6)
Vasopressor use 81.6%
Mechanical ventilation 90.5%
APACHE II = Acute Physiology and Chronic Health Evaluation II; SD = standard deviation; SOFA = Sequential Organ Failure Assessment.
Table 2
Variables used in bivariate analysis
Age (years)
Pre-treatment APACHE II score
Number and type of organ dysfunctions at baseline
Time (hours) from sepsis-induced organ dysfunction to DrotAA administration
Baseline vasopressor status (on vasopressors or not on vasopressors)
Baseline ventilator status (ventilated or not ventilated)
Baseline laboratory values and changes over time:
• platelet count
￿ serum creatinine
￿ protein C
￿ prothrombin time
Baseline and Day 1 SOFA scores
Study site participation in PROWESS [19] (participated in PROWESS or did not participate in PROWESS)
APACHE = Acute Physiologic and Chronic Health Evaluation; DrotAA = Drotrecogin alfa activated; PROWESS = Recombinant human activated 
protein C worldwide evaluation in severe sepsis; SOFA = Sequential Organ Failure Assessment.Available online http://ccforum.com/content/13/3/R78
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Effect of early versus late treatment with DrotAA
A number of significant mortality predictors were identified by
the bivariate analysis: age, baseline Sequential Organ Failure
Assessment (SOFA) respiratory score, baseline prothrombin
time, number of organ failures at baseline, pre-infusion
APACHE II score, baseline SOFA cardiovascular score,
change in platelets, and change in creatinine.
The interaction between age and early versus late treatment
with DrotAA was examined in the predefined clinical subgroup
stable or worsening (n = 242). For these patients, early treat-
ment with DrotAA was associated with lower mortality regard-
less of age (P = 0.0409; Table 4).
Table 5 displays the odds ratio estimates of dying for those
variables found to be significant independent predictors of 28-
day mortality. The results suggest that when treated with
DrotAA, patients aged 49 years and younger have lower odds
of mortality than those 65 years and older (odds ratio: 0.25 to
0.27), and that each six-hour delay in starting DrotAA after the
first sepsis-induced organ dysfunction was associated with a
23% higher odds of mortality (odds ratio: 1.23). A rise in
serum creatinine of 50 μmol/L from baseline to day 1
increased the odds of mortality by 32% (odds ratio: 1.32),
whereas an increase in platelet count of 50 × 109/L from base-
line to day 1 decreased the odds of mortality by 34% (odds
ratio: 0.66).
Safety
Bleeding was the only serious adverse event related to DrotAA
administration. Serious bleeding events were defined as life-
threatening or disabling events, intracranial hemorrhage, or
bleeding that required transfusions for two consecutive days.
A descriptive analysis comparing the Canadian and non-Cana-
dian cohorts revealed that in the Canadian cohort, bleeding
events were relatively few and less frequent compared with
non-Canadian sites. For example, during the 96-hour infusion
period, 2% of Canadian patients had serious hemorrhage (ver-
sus 3.8% of non-Canadian patients), and 0.3% had intracra-
nial hemorrhage (versus 0.7% of non-Canadian patients). In
the 28-day study period (which included the 96-hour infusion),
serious bleeds occurred in 3.9% of Canadian patients (6.9%
of non-Canadian patients).
Discussion
In severe sepsis there is uncertainty as to which clinical pre-
dictors may be valuable in determining whether a patient's clin-
ical status is stable or not. Our study suggests that several
Table 3
Variables associated with 28-day mortality in Canadian sites in ENHANCE
Survivors
Mean (SD)
Non-survivors
Mean (SD)
P value*
Age – years 55.4 (17.4) 62.3 (15.4) 0.0014
Change in serum creatinine (μmol/L), pre-infusion** to day 1 2.8 (85.7) 31.0 (66.0) 0.0011
Change in platelet count (× 109/L) from pre-infusion to day 1 -10.2 (47.7) -27.6 (59.0) 0.0052
Number of organ dysfunctions per patient at baseline 3.0 (1.16) 3.4 (1.088) 0.0073
Baseline APACHE II score 24.7 (7.65) 27.4 (8.153) 0.0100
Time to treatment – hours 26.1 (11.3) 27.6 (14.0) 0.2447
Time to treatment
<24 hours
80.9% 19.1% 0.1788
Time to treatment ≥24 hours 74.4% 25.6%
* P value is based on a one-sided Wilcoxon rank sums test; ** lowest creatinine recorded pre-infusion.
APACHE = Acute Physiologic and Chronic Health Evaluation; SD = standard deviation.
Table 4
28-Day mortality and early versus late treatment with DrotAA in 
patients with clinically stable or worsening status*
Age years DrotAA <24 hours DrotAA ≥24 hours P value
n/N % Mortality n/N % Mortality
≤49 3/34 8.80 6/44 13.60 0.0409
50 to 64 3/27 11.10 12/43 27.90
65 to 74 5/24 20.80 9/25 36.00
≥75 6/22 27.27 8/23 34.78
P value was based on Cochran-Mantel-Haenszel test adjusted for 
age (Breslow-Day P > 0.05). * Defined by first day change in serum 
creatinine or platelet count.
DrotAA = Drotrecogin alfa activated; n = number of patients who 
died by day 28; N = total number of patients.Critical Care    Vol 13 No 3    Hodder et al.
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readily available variables may be potential early clinical pre-
dictors of outcome, and that, when indicated, early rather than
late administration of DrotAA is associated with improved out-
come in severe sepsis. This retrospective analysis suggests
that in combination with other treatment modalities, when indi-
cated, DrotAA administered within 24 hours of the first sepsis-
induced organ dysfunction, may result in significant survival
benefits for patients across the age spectrum studied. This
holds true for patients demonstrating a stable or worsening
clinical status, at least as defined by dynamic changes in
serum creatinine level and in platelet count.
Mortality predictors in severe sepsis
Our initial analysis revealed that in patients administered
DrotAA, two baseline measures of severity – mean number of
organ dysfunctions and APACHE II score – and two dynamic
laboratory measures – serum creatinine and platelet count –
were associated with 28-day mortality. Following a logistic
regression for independent predictors, only a subset of the
variables remained statistically significant: age, first day
change in serum creatinine, first day change in platelet count,
and time to treatment.
Most clinical studies have utilized 'static' characteristics
obtained at baseline to predict mortality. The finding in the cur-
rent analysis that early changes in serum creatinine and plate-
let count were independent predictors of mortality has direct
clinical implications. In the rapidly changing environment of
severe sepsis, it is helpful to identify predictors that reflect
evolving rather than simply baseline status. The idea that iden-
tification of early dynamic predictors of mortality could be very
useful in guiding therapy has recently been suggested from an
analysis of dynamic coagulation changes in sepsis [18]. Dhai-
naut and colleagues found that continued or worsening coag-
ulopathy during the first day of severe sepsis was associated
with new organ failure and increased mortality at 28 days [18].
Data from an integrated sepsis database also provides evi-
dence that serum creatinine change within the first post-base-
line day is predictive of outcome [8]. Other outcome
predictors have been identified in severe sepsis [7,25]. Micek
and colleagues observed that the number of organ dysfunc-
tions (adjusted odds ratio: 2.30) and inappropriate antimicro-
bial treatments (adjusted odds ratio: 15.5) were independent
predictors of mortality [7]. In addition, Johnston found that
baseline platelet counts less than 80 × 109/L carried an odds
ratio of death of 2.05 and a baseline prothrombin time greater
than 30 was associated with an odds ratio of death of 2.88 in
severe sepsis [25].
Time to treatment with DrotAA and 28-day mortality
We observed that the risk of mortality based on odds ratios
increased by 23% with each six-hour delay in receiving
DrotAA. Because this was seen only in the retrospective sub-
group analysis, it could be merely reflective of chance. On the
other hand, there could be subsets of patients who will benefit
more from earlier treatment. This possibility is supported by
others who also found value in early treatment [4,26]. In an
analysis of the full ENHANCE sample, the adjusted odds of
death were 21.8% higher for patients treated later than 24
hours after the first sepsis-induced organ dysfunction, com-
Table 5
Odds ratio estimates of 28-day mortality for patients receiving DrotAA
Variable Odds ratio estimate (95% CI) P value
Age, years
≤49 vs 50 to 64 0.524 (0.2203 to 1.2461) 0.144
≤49 vs 65 to 74 0.251 (0.102 to 0.617) 0.003*
≤49 vs ≥75 0.269 (0.106 to 0.678) 0.005*
50 to 64 vs 65 to 74 0.479 (0.2146 to 1.0676) 0.072
50 to 64 vs ≥75 0.513 (0.2226 to 1.1802) 0.116
65 to 74 vs ≥75 1.071(0.4524 to 2.5346) 0.876
Time to treatment
Delay in time from first sepsis-induced organ dysfunction to start of study drug (six-hour intervals) 1.231 (1.053 to 1.439) 0.009*
Laboratory values
Increase in creatinine from baseline to day 1 (50 μmol/L intervals) 1.317 (1.033 to 1.679) 0.026*
Increase in platelets from baseline to day 1 (50 × 109/L unit intervals) 0.658 (0.442 to 0.978) 0.039*
* statistically significant. CI = confidence interval; DrotAA = Drotrecogin alfa activatedAvailable online http://ccforum.com/content/13/3/R78
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pared with treatment within 24 hours, although the association
was not statistically significant when adjusted for age [6]. In
the current analysis, when a further breakdown of age was
used and the time to treatment effect was based on odds
ratios for death, time to treatment remained statistically signif-
icant after adjusting for age. However, as this is a post hoc,
exploratory analysis, this should be considered as hypothesis-
generating only, and interpretation should be made with cau-
tion.
Others have also observed value in early treatment of severe
sepsis with DrotAA. A recent meta-analysis of five clinical trials
using DrotAA found that patients treated within 24 hours of
first sepsis-induced organ dysfunction had significantly higher
28-day survival compared with those treated later than 24
hours (76.4% versus 73.5%) [27]. These investigators also
found that in their adjusted model, logistic regression analysis
suggested that treatment with DrotAA within 24 hours of
organ dysfunction was associated with lower odds of death
(23%), compared with treatment after 24 hours. In a prospec-
tive study of mortality predictors by Micek and colleagues, the
time to treatment with DrotAA in survivors was significantly
earlier (16.9 hours, standard deviation (SD) 11.9 hours) com-
pared with non-survivors (25.5 hours, SD 28.0 hours) [7].
Most recently, Kanji and colleagues, in a Canadian observa-
tional study, also found that early treatment with DrotAA
(within 12 hours of first organ dysfunction) was associated
with a lower risk of death [28].
Factors associated with delayed aggressive intervention 
in severe sepsis
International guidelines for the management of severe sepsis
suggest the use of DrotAA for patients at high risk of death
[13]. Furthermore, results from the current exploratory evalua-
tion suggest that treatment with DrotAA should be initiated as
soon as possible in all patients with sepsis-induced organ dys-
function who meet criteria for its administration. However,
delays in initiating treatment with DrotAA in Canada are com-
mon – in a registry of 4087 Canadian intensive care patients
(1269 with severe sepsis), the average time to treatment with
DrotAA after identification of organ dysfunction was 1.3 days
[29]. Others have highlighted potentially harmful conse-
quences of delayed therapy with DrotAA [27]. A meta-analysis
in 4459 patients demonstrated that delays in treatment were
directly correlated with the number of organ dysfunctions, the
need for mechanical ventilation or vasopressors, or recent sur-
gery [27]. In addition, that analysis found an inverse relation-
ship between baseline APACHE II score and time to treatment
[27]. Some practice guidelines [20] recommend that DrotAA
be withheld when the clinical course is uncertain, which may
further contribute to worsening clinical status and delays in
therapy. Some clinicians may thus wait for an APACHE II
score to exceed 25 before starting DrotAA, as suggested by
the Food and Drug Administration [25], despite the fact that
APACHE scoring has been validated as a static baseline
measure only in populations and not in individual patients, and
despite the fact that multiple organ dysfunction may be
improving or worsening in the face of no or minor changes in
APACHE score. Inherent in such delays in escalating therapy
may be the impression held by some that apparent clinical sta-
bility is a sign that the patient with severe sepsis may soon
begin to improve with the current level of therapy.
The concept of a false sense of security due to apparent clin-
ical stability may be particularly important when one considers
that the clinician's impression of what constitutes clinical sta-
bility is usually based on 'macroscopic' observations (e.g.
blood pressure, urine output, need for vasopressors etc),
whereas the underlying pathophysiology of severe sepsis is
best defined in terms of a pathologic microcirculation [17,30].
For example, it has been demonstrated that microvascular dys-
function can persist in at least 40% of patients who appear
clinically stable [11]. Apparent clinical stability may thus not
reflect underlying pathophysiology nor predict survival in
severe sepsis. Deficits in microvascular function are present at
the earliest stages of sepsis and improved tissue oxygen deliv-
ery relative to tissue oxygen demand may prevent progression
of sepsis [22]. Treatment addressing 'hidden' microvascular
dysfunction may be one potential explanation of why clinically
stable patients appear to benefit from early treatment with
DrotAA [31]. Treatment with DrotAA may reduce microvascu-
lar inflammation and coagulation, and thus improve function
and tissue oxygenation.
Ideally therefore, aggressive medical intervention for the
reversal of organ dysfunction should be initiated by addressing
microvascular dysfunction, inflammatory response, and coag-
ulopathy. However, escalation of therapy is usually based on
clinical status and is thus often reserved for patients who are
overtly deteriorating or at immediate risk of death. Clinicians
may therefore hold off intervention with DrotAA or other
aggressive resuscitation measures if they interpret that a
patient is 'stable', and may wait a significant amount of time in
order to determine a 'clear' increased or increasing risk of
death.
On the other hand, because many clinicians increasingly view
clinical stability in severe sepsis as having a similar outcome to
worsening clinical status, we attempted to explore the impact
of DrotAA therapy in patients who were defined to be clinically
stable or worsening, based on changes in serum creatinine
and platelet count. Although the intent was to perform the
analysis in a way that mimicked actual clinical practice, com-
bining stable patients with the worsening group does intro-
duce a potential limitation, particularly because these
definitions were determined post hoc. For example, it is possi-
ble that some patients who were started on DrotAA during the
first 24 hours after presentation may have received drug
before changes in creatinine and or platelet counts were
observed. It should be emphasized, therefore, that the presentCritical Care    Vol 13 No 3    Hodder et al.
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analysis is exploratory for the purpose of hypothesis genera-
tion, and that we cannot at present recommend that serial
changes in creatinine or platelet count be used as a guide as
to whether or not or when DrotAA should be given. In addition,
although an attempt was made to mimic 'real world' clinical
decision-making, stable patients made up the largest sub-
group (n = 162) as defined by measures of stability in serum
creatinine and platelet count. Inclusion of these patients with
worsening clinical status as defined may have biased the
results. Nevertheless, because delays in therapy with DrotAA
are associated with increased mortality, we believe that the
concept of apparent clinical stability as a guide to the aggres-
siveness of therapy for severe sepsis should be validated in a
larger cohort.
This retrospective subset analysis of the open-label
ENHANCE trial has a number of other limitations because of
the post hoc and subgroup analyses. A sample size of 305
homogeneous patients may have biased the results because
of a lack of power. Furthermore, predictor variables were col-
lected during the administration of DrotAA, which may con-
found the prognostic validity of mortality predictors with the
effects of treatment with DrotAA. In addition, the observed
improvement in survival associated with early use of DrotAA
may have been a marker for patients who received earlier and
more aggressive resuscitation in the first place (i.e. early goal-
directed therapy [11]). An analysis of the original global
ENHANCE data suggests that this is unlikely, as well as the
fact that this was a relatively new concept during the enrol-
ment period. In the global ENHANCE study, patients treated
later (>24 hours) were more likely to be male and older and to
have had recent surgery. Patients treated later most likely had
more severe disease as suggested by a greater need for vaso-
pressors and mechanical ventilation, and a greater number of
organ dysfunctions, and total SOFA score [6]. Patients treated
earlier had significantly lower 28-day all-cause mortality
(22.9%) than those treated later (27.4%) [6].
Conclusions
This exploratory analysis provides further evidence for two
hypotheses. First, that there are readily available early clinical
predictors of outcome that may be valuable in assessing risk
in the dynamic setting in severe sepsis. Indeed, we observed
that apparent stability of serum creatinine and platelet counts
was associated with significantly increased 28-day mortality.
Second, early treatment with DrotAA (within 24 hours of onset
of sepsis-associated organ dysfunction) may confer a survival
benefit compared with later treatment. Waiting until clear
signs of clinical deterioration are present before initiating treat-
ments for severe sepsis may represent a lost opportunity for
improvement and confer a worse prognosis. These results
should be considered preliminary and hypothesis generating
and require validation using a larger prospective sample. Spe-
cifically, this exploratory analysis suggests that future clinical
trials in sepsis should include provision for prospectively col-
lecting data during the first 24 hours on early dynamic
changes in easily measured variables that might help develop
a reliable predictive index to help identify patients most likely
to benefit from the most aggressive therapies available.
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